ADDITIONAL SOUTHERN CALIFORNIA BREAST HEALTH CENTERS ADD DIGNICAP® TO THEIR PATIENT TREATMENT OFFERINGS


Lund, Sweden—October 4, 2016—Dignitana (http://www.dignitana.se/eng/) AB, a
world leader in medical scalp-cooling technology, announced today that the
DigniCap (https://www.dignicap.com/)® scalp cooling system, which was cleared in
2015 by the FDA to effectively reduce the likelihood of chemotherapy-induced
hair loss in women with breast cancer, will be available at all five
Breastlink (http://www.breastlink.com/) centers in the U.S.  The DigniCap®
system is the first and only scalp cooling device to complete rigorous FDA
clinical trials in America, where seven out of ten patients with early-stage
breast cancer kept at least 50% of their hair.

On the heels of the FDA Clearance, medical centers across the country have begun
offering the DigniCap® scalp cooling system as part of the comprehensive cancer
care treatment services they provide. Through funding from a recent Private
Placement and Rights Offering, Dignitana’s US presence is rapidly expanding as
demand for the medical device accelerates. Breastlink, a comprehensive breast
health center with five locations in Southern California will be offering
DigniCap® scalp cooling systems as part of their breast cancer treatment and
care regimens. Breastlink offers women a comprehensive breast cancer risk
assessment program to help empower them about their health care options.

DigniCap® scalp cooling system will be offered in all of the Breastlink Health
Centers. Locations are as follows:

  · Breastlink (http://www.breastlink.com/centers/breastlink-laguna
-hills/) Laguna Hills, California

  · Breastlink (http://www.breastlink.com/centers/breastlink-temecula
-valley/) Temecula Valley, California

  · Breastlink (http://www.breastlink.com/centers/breastlink-newport
-beach/) Newport Beach, California

  · Breastlink (http://www.breastlink.com/centers/breastlink-orange/) Orange,
California

  · Breastlink (http://www.breastlink.com/centers/breastlink-encino/) Encino,
California

“We are pleased with the consistent strong growth we are experiencing in the
U.S. since FDA clearance nine months ago,” said Jan Richardsson, Chief Executive
Officer of Dignitana. “The DigniCap system is being included as an integral part
of the treatments offered by national leaders in comprehensive breast health
services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have
been ordered for installation by US customers.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone
cooling cap that is placed directly on the head, and an outer neoprene cap that
insulates and secures the silicone cap. The cooling cap is connected to a
cooling and control unit with touch screen prompts. A liquid coolant circulates
throughout the silicone cap, delivering consistent and controlled cooling to all
areas of the scalp. The cap is fitted to the head, and the temperature of the
scalp is lowered, resulting in vasoconstriction with reduced delivery of
chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to
decreased intra follicular metabolic rate. These factors together reduce the
risk of chemotherapy-induced hair loss.
För ytterligare information vänligen kontakta:

Jan Richardsson
VD, Dignitana AB (publ)

Telefon: 046-16 30 92
E-post: jan.richardsson@dignitana.se
Om Dignitana AB (publ)
Dignitanas, med säte i Lund, affärsidé är att utveckla, tillverka och
marknadsföra den medicintekniska produkten DigniCap®. Dignitana bedriver en
kontinuerlig forskning och utveckling av nya användningsområden för DigniCap®.
Dignitanas aktier handlas på NASDAQ OMX First North med Erik Penser Bank som
Certified Adviser. För mer information gå in på: www.dignitana.se

Om skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet DigniCap® - är ett patenterat
system med syfte att eliminera eller kraftigt reducera håravfall för patienter
som genomgår cytostatikabehandling. DigniCap® erbjuder skalpkylning med jämn
kyla, hög effektivitet, säkerhet och acceptabel komfort.

Attachments

10043515.pdf